Gujarat Themis Biosyn Q1 Results FY27: Date, Revenue Estimates, Key Catalysts and Share Price Target

Gujarat Themis Biosyn Q1 Results FY27 is coming into focus as investors position ahead of the July-August 2026 results season, with Gujarat Themis Biosyn shares trading at Rs.385 against a market capitalisation of Rs.4,209 Cr and a price-to-earnings multiple of Not meaningful. As a pharmaceuticals and life sciences name on the NSE and BSE, Gujarat Themis Biosyn enters the Gujarat Themis Biosyn Q1 Results FY27 print with the Street watching revenue momentum, margin trajectory and management commentary on FY27 guidance.

Quarterly financials for Gujarat Themis Biosyn are not yet fully available on Univest’s data partners for this cycle; investors should track Screener.in and the NSE/BSE filings directly for the Gujarat Themis Biosyn Q1 Results FY27 result date and cross-check any figures before making investment decisions.

Get Free Investment Predictions and Gujarat Themis Biosyn Research at Univest

Gujarat Themis Biosyn (NSE: GUJTHEM) operates in the pharmaceuticals and life sciences space and is tracked on Univest under its NSE and BSE listings ahead of the Gujarat Themis Biosyn Q1 Results FY27 season, forming the base against which the Gujarat Themis Biosyn Q1 Results FY27 estimates in this article are built. This Gujarat Themis Biosyn Q1 Results FY27 snapshot is intended as a starting point for research, not a substitute for the company’s own disclosures.

Gujarat Themis Biosyn Q1 FY27 Estimates

Metric	Detail
CMP	Rs.385
Market Cap	Rs.4,209 Cr
Results Date	July-August 2026 (indicative)
12-Month Target (Uniresearch Estimate)	Rs.389-439

Univest, a SEBI-Registered Investment Advisor, Tracks Gujarat Themis Biosyn Ahead of Q1 FY27 Results

Key Catalysts to Watch

1. CDMO Pipeline Visibility

Steady traction in the CDMO and contract manufacturing pipeline supporting revenue visibility is one of the primary variables that analysts are tracking ahead of Gujarat Themis Biosyn’s Q1 FY27 results and FY27 guidance. The market’s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the Gujarat Themis Biosyn share price target or faces renewed pressure.

2. New Product Approvals

New product approvals and launches adding to the domestic and export portfolio is one of the primary variables that analysts are tracking ahead of Gujarat Themis Biosyn’s Q1 FY27 results and FY27 guidance. The market’s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the Gujarat Themis Biosyn share price target or faces renewed pressure.

3. Capacity Scale-Up

Operating leverage from scale-up in recently commissioned manufacturing capacity is one of the primary variables that analysts are tracking ahead of Gujarat Themis Biosyn’s Q1 FY27 results and FY27 guidance. The market’s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the Gujarat Themis Biosyn share price target or faces renewed pressure.

Download the Univest iOS App or Univest Android App to track Gujarat Themis Biosyn’s live price and Q1 FY27 result updates.

Key Risks to the Gujarat Themis Biosyn Q1 Results FY27 Outlook

• Pricing pressure in key export markets, particularly the US generics segment.
• Regulatory or plant compliance issues affecting supply continuity.
• R&D and capacity expansion costs weighing on near-term profitability.

Recent Performance Context

Detailed recent-quarter financials for Gujarat Themis Biosyn were not available from Univest’s data partners at the time of writing. Investors should check Screener.in or the company’s exchange filings for the latest verified numbers before the Q1 FY27 results.

Technical Analysis Ahead of Gujarat Themis Biosyn Q1 Results FY27

Gujarat Themis Biosyn shares last traded at Rs.385. For the current 52-week high and low, support and resistance levels, investors should check the live chart on the Univest app or the NSE website, since these levels move intraday and are not reproduced here to avoid stale data.

Share Price Target Based on the Gujarat Themis Biosyn Q1 Results FY27 Outlook

3-6 Month Target

Over a 3-6 month horizon, the Gujarat Themis Biosyn Q1 Results FY27 trailing-growth framework points to a range of Rs.378-408 for Gujarat Themis Biosyn, contingent on the Gujarat Themis Biosyn Q1 Results FY27 print matching or beating the trailing growth trend.

12-Month Target

The 12-month target (Uniresearch estimate) tied to this Gujarat Themis Biosyn Q1 Results FY27 view for Gujarat Themis Biosyn works out to Rs.389-439, built on the same trailing revenue growth trend and current valuation multiple. Tracking is how Univest research categorises the stock heading into Gujarat Themis Biosyn Q1 Results FY27, not a formal Buy or Sell call.

FY27-28 Outlook

Looking out to FY27-28, a sustained continuation of the growth trajectory implied by this Gujarat Themis Biosyn Q1 Results FY27 analysis would put Gujarat Themis Biosyn in a Rs.410-480 range, though this is sensitive to sector-wide demand, cost trends and any change in the company’s competitive position.

What to Watch in the Gujarat Themis Biosyn Q1 Results FY27 Print

• Revenue and PAT versus the Gujarat Themis Biosyn Q1 Results FY27 estimate range in this preview.
• Management commentary on FY27 growth guidance and margin trajectory relevant to the Gujarat Themis Biosyn Q1 Results FY27 narrative.
• Steady traction in the CDMO and contract manufacturing pipeline supporting revenue visibility
• Pricing pressure in key export markets, particularly the US generics segment

Conclusion on Gujarat Themis Biosyn Q1 Results FY27

Gujarat Themis Biosyn enters the Q1 FY27 results season trading at Rs.385, with the 12-month Uniresearch target range of Rs.389-439 reflecting a tracking stance. Investors tracking the Gujarat Themis Biosyn Q1 Results FY27 print should watch the catalysts and risks above and consult a SEBI-registered advisor before making investment decisions around the results.

FAQs on Gujarat Themis Biosyn Q1 Results FY27

When are Gujarat Themis Biosyn Q1 FY27 results expected?

Ans. Gujarat Themis Biosyn’s Q1 FY27 results are expected in the July-August 2026 window, in line with the broader NSE and BSE results season for the quarter ending June 2026.

What is the Gujarat Themis Biosyn Q1 FY27 revenue estimate?

Ans. Detailed quarterly estimates are not available for Gujarat Themis Biosyn at this time; check Screener.in or the company’s exchange filings for verified numbers.

What is the Gujarat Themis Biosyn share price target?

Ans. The 12-month Uniresearch estimate for Gujarat Themis Biosyn share price target is Rs.389-439, based on trailing growth and current valuation multiples.

Is Gujarat Themis Biosyn a good buy before Q1 FY27 results?

Ans. Gujarat Themis Biosyn is tracking heading into Q1 FY27 results. Investors should weigh the catalysts and risks in this article and consult a SEBI-registered advisor before investing.

What should investors watch in Gujarat Themis Biosyn’s Q1 FY27 results?

Ans. Key items include revenue and PAT versus estimates, management commentary on FY27 guidance, and steady traction in the CDMO and contract manufacturing pipeline supporting revenue visibility.

Where can I track Gujarat Themis Biosyn share price live?

Ans. Gujarat Themis Biosyn share price can be tracked live on the Univest app and website, along with research updates from SEBI-registered analysts.